Source-of-truth pathways for high-risk populations
Tenured Associate Professor and Founding Director of Tulane's Health Psychology doctoral program
Publishes the PMC U.S. COVID weekly report and technical appendix for clinicians and communities
Integrates IHME infection estimates with Biobot and CDC wastewater signals using explicit assumptions
We are building an evidence-forward pathway, not a personality cult and not a political silo.
Live FDA Diagnostics Link (Always Current): We route directly to the official source so users always see current guidance instead of a static copy.
FDA Home COVID-19 Diagnostic Tests Frequently Asked Questions
Current literature indicates that people with hematological malignancies (for example leukemia, lymphoma, and multiple myeloma) can face materially higher severe-COVID risk than many solid-tumor cohorts.
This page is a bridge to evidence pathways. Users should review primary sources and discuss decisions with licensed clinicians who know their specific medical context.
At-home diagnostics can support early action, but they should be used exactly as instructed and interpreted cautiously. Antigen tests are convenient, while molecular/NAAT options are generally more sensitive.
For the latest authorized products, repeat-test schedules, and handling guidance, use the live FDA page: Home COVID-19 Diagnostic Tests: Frequently Asked Questions.
The following list provides the primary sources used for the clinical analysis of COVID-19 outcomes and mitigation strategies across high-risk populations.
Note: These resources provide primary data and clinical insights regarding COVID-19 and long-term health sequelae across cohorts including cancer, cognitive disorders, and metabolic conditions.
CareHub provides anonymous bulletin board participation plus anonymous audio and video chats with no recording, designed to reduce fear of stigma while preserving personal agency and privacy.